Asco 2021 – Merus’s slight improvement might not win over investors
The group still has its eye on accelerated approval, though genetic testing casts a long shadow.
Asco 2021 – Abstract lift drives first stock moves
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
SITC 2020 – second chances for Merck & Co and Oncosec
Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.
SITC 2019 preview – Pieris joins the quest for a better Herceptin
Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
Triple meeting – targeted focus validates Merus’s change of tack
Merus’s anti-Her2/Her3 bispecific could have a future in a new targeted setting.
Corporate venture firms – dedicated followers of fashion?
Eagerly pursuing all the latest fads and trends.
